Q-Med trading update for the fourth quarter of 2008


Q-Med trading update for the fourth quarter of 2008

In order to ensure that shareholders have up to date information to make their
decision in relation to the public tender offer from Ivytan AB (the “Offer”) for
the shares of Q-Med AB (publ) (“Q-Med” or the “Company”), the Company has deemed
it appropriate to provide an interim trading update for the fourth quarter of
2008. However, it should be noted that there remains a high degree of
uncertainty given the current economic environment.

Q-Med's revenues in October and November to date have remained at comparable
levels to the same period of 2007. If revenue development continues at the same
rate as October and November to date, total revenues for the fourth quarter of
2008 will be in line with revenues reported for the same period of 2007. 

In October, Q-Med increased the level of investment in marketing and sales
relating to the continuing launch of Macrolane™ and Restylane Vital™, and
increased its direct sales presence in a number of strategic markets. This has
contributed to a lower overall operating profit margin for the month of October
compared to the third quarter of 2008. Assuming that the operating profit margin
for October is maintained, the overall operating profit margin for the fourth
quarter (excluding restructuring costs and expenses relating to the Offer) will
be in line with the level reported for the first three quarters of 2008.

In addition, the previously announced restructuring costs of 25-30 MSEK and
expenses relating to the Offer will be charged in the fourth quarter of 2008.

Queries should be addressed to: 
Alexander Kotsinas, Vice President and CFO
Tel: +46 (0)73-500 1111
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70-974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.

Attachments

11252033.pdf